Health AI Central
Share:
Peer-Reviewed Publication
J Pathol Clin Res2026;12(2):e70083.March 1, 2026Journal Article

Spatial heterogeneity of antibody-drug conjugate targets in pancreatic ductal adenocarcinoma.

Deema Sabtan1, Marie-Lisa Eich1, Florian Loch2, Julen Karl Pérez Zuschneid1, Markus Möbs1, Judith Böhme1, Frederick Klauschen1,3,4,5,6,7, David Horst1,3, Mihnea P Dragomir1,3,4, Gabriel Dernbach1,8, Simon Schallenberg1,3
1Institute of Pathology, Charite, Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.
2Department of Surgery, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
3German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Partner Site Berlin, Heidelberg, Germany.
4Berlin Institute of Health, Charite, Universitätsmedizin Berlin, Berlin, Germany.
5Institute of Pathology, Ludwig Maximilians University, Munich, Germany.
6Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Munich Partner Site, Heidelberg, Germany.
7BIFOLD-Berlin, Institute for the Foundations of Learning and Data, Berlin, Germany.
8Aignostics GmbH, Berlin, Germany.
PubMed PMC DOI PDF

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease, with limited therapeutic options, few patients showing targetable molecular changes. New therapeutic strategies are necessary. Antibody-drug conjugates (ADCs) have emerged as alternative therapeutic strategies across various cancer types. Herein, we analyze the expression and spatial heterogeneity (six cores per patients) of three ADC ta…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.